Abstract
The pharmacokinetics of mezlocillin were studied in 31 children (age, 2 to 19 years) with malignancies and normal renal and hepatic functions. Mezlocillin was administered intravenously over 30 min every 4 h at doses ranging from 12.2 to 125 mg/kg. Blood samples were obtained over one dosage interval at steady state. For all patients, the mean clearance was 0.21 +/- 0.11 liter/h per kg, the mean distribution volume was 0.26 +/- 0.13 liter/kg, and the mean elimination half-life was 0.97 +/- 0.51 h. Trough concentrations were 23.0 +/- 29.9 mg/liter before the dose was administered and 20.4 +/- 27.5 mg/liter at the end of the dosing interval. Peak concentrations averaged 245 +/- 90.4 mg/liter, and average concentrations for the dosing interval were 83.7 +/- 40.4 mg/liter. There were no apparent effects of sex, malignancy, age, or dose on either the kinetic parameters or plasma concentrations. Overall, the disposition parameters for mezlocillin in this patient group were comparable to those reported in adults.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aronoff G. R., Sloan R. S., Luft F. C., Nelson R. L., Maxwell D. R., Kleit S. A. Mezlocillin pharmacokinetics in renal impairment. Clin Pharmacol Ther. 1980 Oct;28(4):523–528. doi: 10.1038/clpt.1980.197. [DOI] [PubMed] [Google Scholar]
- Bergan T., Brodwall E. K., Wiik-Larsen E. Mezlocillin pharmacokinetics in patients with normal and impaired renal functions. Antimicrob Agents Chemother. 1979 Nov;16(5):651–654. doi: 10.1128/aac.16.5.651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bergan T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother. 1978 Dec;14(6):801–806. doi: 10.1128/aac.14.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Francke E., Mehta S., Neu H. C., Appel G. B. Kinetics of intravenous mezlocillin in chronic hemodialysis patients. Clin Pharmacol Ther. 1979 Aug;26(2):228–231. doi: 10.1002/cpt1979262228. [DOI] [PubMed] [Google Scholar]
- Friis-Hansen B. Body composition during growth. In vivo measurements and biochemical data correlated to differential anatomical growth. Pediatrics. 1971 Jan;47(1 Suppl):264+–264+. [PubMed] [Google Scholar]
- Frimodt-Möller N., Maigaard S., Toothaker R. D., Bundtzen R. W., Brodey M. V., Craig W. A., Welling P. G., Madsen P. O. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function. Antimicrob Agents Chemother. 1980 Apr;17(4):599–607. doi: 10.1128/aac.17.4.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kampf D., Schurig R., Weihermüller K., Förster D. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Antimicrob Agents Chemother. 1980 Jul;18(1):81–87. doi: 10.1128/aac.18.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pickering L. K., Kramer W. G., Armes D. A., Frankel L. S., Townsend I. R., Culbert S. Clinical pharmacology and efficacy of mezlocillin in paediatric patients with malignancy. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):245–250. doi: 10.1093/jac/9.suppl_a.245. [DOI] [PubMed] [Google Scholar]
- Rubio T., Wirth F., Karotkin E. Pharmacokinetic studies of mezlocillin in newborn infants. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):241–244. doi: 10.1093/jac/9.suppl_a.241. [DOI] [PubMed] [Google Scholar]
- Trujillo H., Bustos-González A., Peláez L. C., Halpert D., Mejía G., Zapata C. T., Taboada B. Mezlocillin in infants and children: efficacy, safety and pharmacokinetics. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):263–265. doi: 10.1093/jac/9.suppl_a.263. [DOI] [PubMed] [Google Scholar]